These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 12654650

  • 21. Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans.
    Lee RE, Liu TT, Barker KS, Lee RE, Rogers PD.
    J Antimicrob Chemother; 2005 May; 55(5):655-62. PubMed ID: 15814599
    [Abstract] [Full Text] [Related]

  • 22. FLO8 deletion leads to azole resistance by upregulating CDR1 and CDR2 in Candida albicans.
    Li WJ, Liu JY, Shi C, Zhao Y, Meng LN, Wu F, Xiang MJ.
    Res Microbiol; 2019 May; 170(6-7):272-279. PubMed ID: 31449848
    [Abstract] [Full Text] [Related]

  • 23. Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.
    Ricardo E, Costa-de-Oliveira S, Dias AS, Guerra J, Rodrigues AG, Pina-Vaz C.
    FEMS Yeast Res; 2009 Jun; 9(4):618-25. PubMed ID: 19416368
    [Abstract] [Full Text] [Related]

  • 24. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.
    Sanglard D, Ischer F, Koymans L, Bille J.
    Antimicrob Agents Chemother; 1998 Feb; 42(2):241-53. PubMed ID: 9527767
    [Abstract] [Full Text] [Related]

  • 25. Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents.
    Henry KW, Cruz MC, Katiyar SK, Edlind TD.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1968-74. PubMed ID: 10428921
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Ncb2 is involved in activated transcription of CDR1 in azole-resistant clinical isolates of Candida albicans.
    Shukla S, Yadav V, Mukhopadhyay G, Prasad R.
    Eukaryot Cell; 2011 Oct; 10(10):1357-66. PubMed ID: 21856931
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Proteomic analysis of azole resistance in Candida albicans clinical isolates.
    Hooshdaran MZ, Barker KS, Hilliard GM, Kusch H, Morschhäuser J, Rogers PD.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2733-5. PubMed ID: 15215138
    [Abstract] [Full Text] [Related]

  • 33. Regulation of azole drug susceptibility by Candida albicans protein kinase CK2.
    Bruno VM, Mitchell AP.
    Mol Microbiol; 2005 Apr; 56(2):559-73. PubMed ID: 15813744
    [Abstract] [Full Text] [Related]

  • 34. The genetic basis of fluconazole resistance development in Candida albicans.
    Morschhäuser J.
    Biochim Biophys Acta; 2002 Jul 18; 1587(2-3):240-8. PubMed ID: 12084466
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Genome-wide expression profiling of the response to terbinafine in Candida albicans using a cDNA microarray analysis.
    Zeng YB, Qian YS, Ma L, Gu HN.
    Chin Med J (Engl); 2007 May 05; 120(9):807-13. PubMed ID: 17531123
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Transcriptional activation and increased mRNA stability contribute to overexpression of CDR1 in azole-resistant Candida albicans.
    Manoharlal R, Gaur NA, Panwar SL, Morschhäuser J, Prasad R.
    Antimicrob Agents Chemother; 2008 Apr 05; 52(4):1481-92. PubMed ID: 18268086
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.